Accepted for Publication: March 4, 2013.
Published Online: August 12, 2013. doi:10.1001/jamaneurol.2013.2831.
Acquisition of data: Dauvilliers, Bauer, Rigau.
Analysis and interpretation of data: Dauvilliers, Bauer, Rigau, Lalloyer, Labauge, Carlander, Lassmann.
Drafting of the manuscript: Dauvilliers, Bauer.
Critical revision of the manuscript for important intellectual content: Dauvilliers, Rigau, Lalloyer, Labauge, Carlander, Liblau, Peyron, Lassmann.
Obtained funding: Dauvilliers.
Administrative, technical, and material support: Dauvilliers, Bauer, Rigau, Lalloyer, Peyron.
Study supervision: Dauvilliers, Labauge.
Conflict of Interest Disclosures: Dr Dauvilliers has received speaker’s honoraria and funding for travel to conferences from UCB Pharma, JAZZ, Novartis, and Bioprojet, and has participated in advisory boards of UCB and Bioprojet. Dr Carlander has received consultancy honoraria from Merck Serono and travel accommodation expenses from Biogen Idec, Merck Serono, Teva, and Novartis. Dr Lassmann serves on scientific advisory boards for Micromet, Biogen, and Baxter, and has given lectures for Novartis, Biogen, and Serono.